Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Completed · Phase 1
Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Radioactive substances, such as samarium 153, may release radiation as it breaks down and kill cancer cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also make tumor cells more sensitive to radiation. Giving samarium 153 together with bortezomib may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of samarium 153 when given together with bortezomib in treating patients with relapsed or refractory multiple myeloma.
Key facts
- Study ID
- NCT00316940
- Run by
- Oncotherapeutics
- People needed
- 36
- Starts
- 2005-12-01
- Expected to finish
- 2011-02-01
- Last updated by the study team
- 2013-09-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Comprehensive Blood and Cancer Center — Bakersfield, California, United States
- Hematology-Oncology Medical Group of Fresno, Incorporated — Fresno, California, United States
- Study site — West Hollywood, California, United States
- Center for Cancer and Blood Disorders at Suburban Hospital — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.